Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced to help manage type 2 diabetes. They improve glycemic control and promote weight loss, which we all know are essential for long-term outcomes. In practice, I’ve seen that their impact goes beyond these traditional targets. Patients often benefit from cardiovascular protection and kidney improvements, and emerging data show advantages in areas we did not initially anticipate, such as sleep apnea, joint health, and physical endurance.

Obstructive sleep apnea

GLP-1 RAs, including tirzepatide and semaglutide, have been shown to lower the apnea-hypopnea index (AHI) in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA). In several trials, reductions reached up to 29 events per hour, and patients reported better daytime functioning. I consider these effects clinically meaningful, especially since they appear even in patients without diabetes. Tirzepatide is now FDA approved for OSA in adults with obesity, and meta-analyses show consistent benefits across multiple studies. That said, tolerability should be a key consideration, as side effects remain more common than with placebo.

Musculoskeletal function

In my experience, GLP-1 RAs can help patients with knee osteoarthritis and other weight-related joint issues. The improvements in pain and function seem to be linked to weight loss and reduced systemic inflammation. Studies with semaglutide support what I see in clinic: Patients often report less pain and better mobility. While we do not yet have evidence that these drugs directly modify the disease, the metabolic improvements alone can have meaningful effects on daily activity and quality of life.

Physical endurance

I have noticed that some patients on GLP-1 therapy become more active simply because they have more energy and less discomfort. Semaglutide has been shown in trials like STRIDE to improve walking capacity in patients with peripheral artery disease. Mechanistic studies suggest this may result from enhanced skeletal muscle metabolism and endurance. In practice, these benefits can translate into more confidence in daily activity, better exercise tolerance, and improved overall function.

Looking ahead

With new incretin-based agents entering the market, our role as clinicians is evolving. We are not only managing glucose and weight but also looking at broader measures of patient health. Staying current with the data and understanding how to integrate these therapies into real-world practice is essential. For me, the most rewarding aspect is seeing patients move more, sleep better, and engage in life in ways they could not before. These practical outcomes often matter as much as any laboratory measure.

Collaborating for safe, effective care

GLP-1 therapies are changing how we think about metabolic health, but collaboration remains key. General physicians are encouraged to involve endocrinology colleagues and follow guidance from professional bodies such as the American College of Diabetology. Their efforts highlight the growing recognition of specialized diabetes care and the importance of coordinated, evidence-based treatment.

Zehra Haider is an internal medicine physician.